Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sapio Sciences Announces Exemplar LIMS for Clinical and Research NGS Labs

Published: Tuesday, February 25, 2014
Last Updated: Tuesday, February 25, 2014
Bookmark and Share
Purpose-built system handles the sample tracking and processing needs of clinical or research laboratories

Sapio Sciences has announced Exemplar LIMS for clinical and research NGS labs.   Exemplar NGS LIMS is a system built to handle the sample tracking and processing needs of clinical or research laboratories. Exemplar provides complete tracking of samples through the NGS pipeline from request through sample processing and results delivery. It provides automation integration as needed, along with preconfigured workflows, management level dashboards, full consumables management and support for regulatory compliance such as CLIA.

The dynamic nature of the NGS lab requires a LIMS that can adapt quickly to changing protocols and platforms. Exemplar is the most configurable LIMS at all levels, meaning that no matter what technology you introduce into your lab or what your requirements are, you can be confident that Exemplar can meet your needs.

When evaluating a LIMS, labs should choose a system that:

Is fully web based for complete end user usage and configuration and is usable on tablet computers.
Tracks volumes of samples through the pipeline
Has pre-built, CLIA standard, NGS workflows
Fully tracks aliquot and derivative lineage
Tracks samples and workflows throughout the pipeline.
Collects quality control data and integrates with all leading QC genomics instruments.
Can fully track consumables including amount remaining in inventory and expiration dates.
Is highly configurable to easily alter existing workflows and when creating new ones.
Includes graphical dashboards of lab activity
Is highly scalable to handle anticipated concurrent users and sample volumes for many years
Can support any additional lab process outside the NGS arena
This extent of this list is daunting for a new MDx company to consider as a thorough implementation of these features could require 4 or more software solutions and years of work. New labs also need to get CLIA certification and may also need to operate under GLP and/or be a validated lab per FDA Part 11 specifications.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Combination Therapy Improved Chemoresistance in Ovarian Cancer
The study demonstrates how an existing class of targeted therapies could be used to potentiate the tumor suppression induced by cisplatin.
Gene Therapy for Blistering Skin Disease Shows Promise
Grafting genetically altered skin onto patients’ chronic wounds marks the first time skin-based gene therapy has been demonstrated to be safe and effective in humans.
Alzheimer’s Treatment Moves a Step Closer
Merck scientists have reported the discovery of verubecestat, a structurally unique, orally bioavailable small molecule that has been shown to target the most visible sign of the disease in the brain.
Lynparza Phase III Progression-Free Survival Benefit
AstraZeneca announces results from Phase III SOLO-2 trial designed to determine the efficacy of Lynparza as a monotherapy for ovarian cancer.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!